Company profile

Organon & Co.

NYSE:OGNBiotechnology: Pharmaceutical Preparations

Drug pipeline (49)

AssetStageRevenueTrialsStatus
ALENDRONATE SODIUMapproved6approved
Betamethasone Acetateapproved0
Betamethasone Dipropionateapproved0
Betamethasone sodium phosphateapproved0
CAFFEINEapproved3approved

Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.

Clinical trials (450)

NCT IDPhaseStatusStartCompletionSponsor nameTitle
NCT00145470phase3completed2005-06-022007-02-28Organon and Co12 Week Study of the Safety/Efficacy of Asenapine When Added to Lithium/Valproate in the Treatment of Bipolar Disorder (A7501008 / P05844 / MK-8274-017)
NCT00159744phase3completed2004-11-302006-04-29Organon and Co3-Week Study of Asenapine, Olanzapine and Placebo for Treatment of Bipolar Mania (P07008)
NCT00159796phase3completed2004-12-142006-03-28Organon and Co3-week Study of Asenapine, Olanzapine and Placebo for Treatment of Bipolar Mania (P07009)
NCT00641771phase1completed2004-05-012005-08-01Organon and Co4-Week Study to Assess the Effect of Alendronate and Vitamin D3 Once Weekly on Fractional Calcium Absorption in Postmenopausal Osteoporotic Women (0217A-230)
NCT00159783phase3completed2005-07-012007-04-01Organon and Co40 Week Extension Study Of Asenapine and Olanzapine For Bipolar Disorder (A7501007)(COMPLETED)(P05857)

FDA applications (66)

ApplicationTypeApplicantProducts
ANDA 080997ANDAORGANON USA INC
ANDA 086562ANDAORGANON USA INC
ANDA 086750ANDAORGANON USA INC
ANDA 087014ANDAORGANON USA INC
ANDA 087535ANDAORGANON USA INC